GlobeNewsWire
04 Nov 2025, 21:05 UTC · 51w ago
Impact · against what's priced in
Tarsus shows strong commercial momentum with XDEMVY sales growing 147% year-over-year to $119 million in Q3 2025. The expansion of the prescriber base and the advancement of Phase 2 pipeline programs provide a positive outlook for sustained growth.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Tarsus Pharmaceuticals reported third quarter 2025 net sales for XDEMVY of approximately $119 million, a 147% increase year-over-year.
More positive than 99% of claims this week
Weekly multi-patient prescribers grew by approximately 30% in the third quarter.
Continue reading
5 related stories
Q3 net sales of $119 million represent a 147% year-over-year increase, supported by a 30% growth in weekly multi-patient prescribers. Pipeline progress in Phase 2 for ocular rosacea and Lyme disease prevention adds long-term optionality.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 92% of claims this week
The company is advancing a pipeline including TP-04 for ocular rosacea and TP-05 for the prevention of Lyme disease, both currently in Phase 2.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company reported strong Q3 2025 results with net sales of XDEMVY up approximately 147% year-over-year and growth in prescribers.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
4h ago
+4.7%
Price agrees with the score
$74.85 vs $71.50 close before publication (Nov 4) · not market-adjusted
TARS chart →
